Spravato billing and coding changed materially in 2026. The permanent HCPCS code J0013 replaced S0013 for many drug billing scenarios, while Medicare combination codes G2082 and G2083 remain central to provider buy-and-bill claims. The correct claim still depends on the payer, benefit channel, drug acquisition method, dose, site of care, and documentation.
That combination makes Spravato different from a routine psychiatric office visit. A treatment session may involve the drug, evaluation and management work, prolonged monitoring, prior authorization, and REMS requirements. Before submitting a claim, your billing team must know who supplied the medication and which coding pathway the payer expects.
Quick Spravato Billing Codes Reference
| Code | General description | Common billing context |
|---|---|---|
| J0013 | Esketamine, nasal spray, 1 mg | Drug code used in many non-Medicare buy-and-bill scenarios, subject to payer policy |
| G2082 | Established outpatient E/M service, up to 56 mg of esketamine, including two hours of post-administration observation | Medicare combination code when the provider supplies the drug |
| G2083 | Established outpatient E/M service, more than 56 mg of esketamine, including two hours of post-administration observation | Medicare combination code commonly associated with an 84 mg dose when the provider supplies the drug |
| 99202 to 99205 or 99212 to 99215 | Office or outpatient E/M codes | Potential professional-service pathway when supported and accepted by the payer |
| 99415, 99416, 99417, or G2212 | Potential prolonged-service codes | Payer-specific monitoring scenarios when time and supervision requirements are met |
This table is a starting point, not a universal claim recipe. Johnson & Johnson’s official SPRAVATO coding and reimbursement resource emphasizes that assignment of a code does not guarantee coverage or payment. Check each patient’s payer policy, authorization, contract terms, and benefit design before treatment.
What Changed in Spravato Billing for 2026?
The major coding change was the introduction of J0013, defined as esketamine nasal spray, 1 mg. This permanent HCPCS code replaced the temporary S0013 pathway for applicable dates of service. Old billing templates that still calculate units based on the former temporary code can produce incorrect claims even when the dose in the chart is right.
J0013 replacing S0013
Because J0013 represents 1 mg, the unit count generally follows the number of milligrams billed. A 56 mg treatment commonly maps to 56 units, and an 84 mg treatment commonly maps to 84 units when J0013 is the payer-approved drug code. Confirm the payer’s unit and NDC instructions before submission.
Do not assume every plan implemented the transition at the same speed. A commercial payer may recognize J0013 but still require a revised authorization, updated fee schedule, or new medical policy configuration. Another plan may route the drug through the pharmacy benefit and expect the specialty pharmacy to bill for it.
Existing authorizations and payer transitions
An authorization approved under S0013 may not automatically cover a claim submitted with J0013. Before ordering medication, confirm that the authorization lists the current code, approved dose, number of treatments, date range, site of care, and servicing provider. Record the payer representative, reference number, date, and exact guidance in the account notes.
This front-end check matters most in buy-and-bill. The practice has already paid for the drug, so a code mismatch can turn a preventable administrative issue into a significant accounts receivable balance.
How Spravato Acquisition Determines the Claim
The first operational question is simple: who purchased and supplied the medication? The answer determines whether the practice should bill the drug, only the professional services, or a payer-defined combination code.
Provider buy-and-bill
Under buy-and-bill, the practice purchases Spravato through an appropriate distribution channel, maintains inventory, administers the treatment, and submits the claim. The payer may require J0013 plus separately supported professional services, or it may require a bundled code such as G2082 or G2083.
Inventory and claims must reconcile. The administered dose, number of devices, units, NDC information, acquisition record, and waste documentation should tell the same story. If the chart documents 84 mg but the claim carries 56 J0013 units, the mismatch is likely to delay payment or trigger a records request.
REMS-certified specialty pharmacy
Some plans process Spravato through the pharmacy benefit. A REMS-certified specialty pharmacy supplies the drug to the treatment site and bills for the medication. In that arrangement, the practice should not bill the drug again. It may bill appropriate professional or monitoring services if the payer covers them and the documentation supports the codes.
Duplicate drug billing is a common failure point. Before charge entry, the biller should see a clear acquisition indicator in the scheduling or medication record: provider stock, specialty-pharmacy supplied, or another payer-approved route. A practice using specialized Spravato billing services should expect this check to occur before every claim, not after a denial.
Spravato Billing Codes Explained
J0013 units for 56 mg and 84 mg
J0013 represents 1 mg of esketamine nasal spray. When a payer accepts J0013 and instructs the provider to bill by milligram, the usual unit logic is:
- A 56 mg treatment is reported as 56 units of J0013.
- An 84 mg treatment is reported as 84 units of J0013.
The unit count is not the number of devices. Each device delivers 28 mg, so a 56 mg dose uses two devices and an 84 mg dose uses three. Billing two or three units of a code defined per milligram would understate the dose. This is exactly the type of error that survives a quick visual review because the number of devices looks reasonable.
G2082 and G2083
G2082 and G2083 are combination codes. G2082 covers up to 56 mg, while G2083 covers more than 56 mg. Their descriptions include the medication, an established outpatient E/M service, supervision of self-administration, and two hours of post-administration observation.
Do not automatically add J0013 to G2082 or G2083. If the G code already includes the drug and associated service, adding a separate drug line can create duplicate billing. Medicare Advantage plans may apply a different benefit pathway, so verify their policy rather than assuming Original Medicare logic applies.
E/M and prolonged-service codes
There is no single CPT code that fits every non-Medicare Spravato session. Some commercial payers allow an office or outpatient E/M code when the encounter includes medically necessary, separately documented E/M work. Code selection must follow the current CPT rules for medical decision making or time.
The required observation period alone does not automatically support an E/M level or prolonged-service code. Documentation should identify who provided the service, start and stop times when time-based coding is used, the clinical work performed, and the patient’s status. Confirm whether the payer accepts 99415, 99416, 99417, G2212, or another pathway before creating a standard claim template.
Medicare vs Commercial Spravato Billing
Medicare and commercial plans may pay the same treatment through different code structures. For a provider buy-and-bill Medicare claim, G2082 or G2083 may package the drug, E/M work, and observation into one code. Commercial plans more often separate the drug from professional services, but their requirements vary widely.
| Question | Medicare pathway | Commercial pathway |
|---|---|---|
| Drug supplied by provider? | G2082 or G2083 may apply | J0013 may apply with correct units |
| Drug supplied by specialty pharmacy? | Confirm plan and MAC guidance | Practice generally does not bill the drug |
| Observation billed separately? | Included when the applicable G code is used | Depends on payer policy and documented service |
| Prior authorization? | Confirm coverage and medical necessity requirements | Commonly required and code-specific |
Build a payer matrix rather than one universal superbill. For every high-volume plan, record the benefit channel, acquisition route, drug code, units, accepted professional codes, NDC format, authorization rules, place of service, and timely filing limit. Update the matrix whenever a denial reveals a policy change.
Four Spravato Billing Scenarios
1. Medicare provider buy-and-bill
The practice supplies the medication and documents an established outpatient encounter with supervised self-administration and the required observation. G2082 generally corresponds to a dose up to 56 mg, while G2083 covers more than 56 mg. The practice should not separately add J0013 when the applicable G code includes the drug.
2. Commercial provider buy-and-bill
The practice purchases the drug, and the payer authorizes it under the medical benefit. The claim may contain J0013 with 56 or 84 units, plus an E/M or prolonged-service code when payer policy permits and the record supports the service. Confirm whether an 11-digit NDC, invoice, modifier, or specific place of service is required.
3. Specialty pharmacy supplies the medication
The specialty pharmacy ships the patient-specific drug to the certified treatment site and bills the medication. The practice bills only covered professional services. It should not report J0013, G2082, or G2083 as though it purchased the drug. A scheduling note should identify the supplying pharmacy before the appointment reaches charge entry.
4. Hospital outpatient department
Hospital outpatient billing may involve a facility claim, professional claim, revenue codes, G0463, or payer-specific drug and monitoring rules. Do not transfer a physician-office claim template directly into an HOPD workflow. Confirm the payer’s facility policy and make sure the drug is not billed on both the facility and professional claims.
REMS and Treatment Documentation
Spravato is available only through a restricted Risk Evaluation and Mitigation Strategy program. The official FDA SPRAVATO REMS information should guide the clinical compliance workflow. Billing staff do not manage the patient’s clinical care, but they must know whether the record supports the services appearing on the claim.
A treatment note should identify the indication, dose, number of devices, acquisition route, administration time, monitoring period, required assessments, adverse effects, interventions, and discharge status. It should also support any separately reported E/M or prolonged service. A generic statement such as “patient observed for two hours” may not establish who provided the service or what clinical work occurred.
Credentialing and enrollment are another operational dependency. The rendering provider, billing entity, location, payer enrollment, and REMS-certified site must align. Adding Spravato without reviewing the practice’s medical credentialing setup can lead to denials even when the clinical documentation and codes are correct.
Prior Authorization Workflow
Prior authorization should be verified before medication is ordered and again before each treatment when an authorization is near its visit or date limit. The approval should match the diagnosis, current HCPCS code, dose, frequency, number of sessions, treatment site, servicing provider, and benefit channel.
- Verify active eligibility and determine whether Spravato falls under the medical or pharmacy benefit.
- Confirm the acquisition route and the payer’s current code for the medication.
- Submit the required clinical history, previous treatment information, treatment plan, and REMS details.
- Record the authorization number, approved units or visits, effective dates, and payer contact reference.
- Track usage and renewal dates before scheduling treatment beyond the approval.
Patient cost questions should be handled before the first session as well. Coverage, deductible, coinsurance, copay assistance, and observation charges can create different patient responsibilities. The SwiftMDS guide to Spravato costs without insurance provides useful context, but the practice should complete a patient-specific benefits investigation rather than quote a general amount.
Common Spravato Denials and Corrections
| Denial pattern | What to check | Corrective action |
|---|---|---|
| Invalid or discontinued drug code | Date of service, J0013 transition, payer policy | Confirm the accepted 2026 code and update the authorization if needed |
| Units do not match the dose | Milligrams, devices, J0013 unit definition | Reconcile the administration record and claim units |
| Duplicate drug billing | Specialty pharmacy supply or G-code inclusion | Remove the unsupported drug line and correct the acquisition indicator |
| Authorization mismatch | Code, dose, site, provider, dates, visits | Request correction or follow the payer’s reconsideration process |
| Monitoring service denied | Payer policy, time records, provider type, code requirements | Appeal only when the policy and documentation support separate payment |
| Provider or location not eligible | Enrollment, credentialing, network, REMS site | Correct the billing setup before resubmitting |
Do not respond to every denial by adding a modifier or changing a code. Start with the remittance reason, payer policy, authorization, and source documentation. A corrected claim changes inaccurate claim data. An appeal defends accurate data that the payer processed incorrectly. Mixing those paths adds delay.
Pre-Submission Spravato Claim Checklist
- Eligibility is active, and the medical or pharmacy benefit channel is documented.
- The authorization matches the current code, dose, dates, provider, location, and remaining sessions.
- The claim identifies whether the provider or specialty pharmacy supplied the drug.
- J0013 units match the milligrams administered when that code is used.
- G2082 or G2083 is not paired with a duplicate drug charge.
- E/M and prolonged-service codes are accepted by the payer and supported by the note.
- NDC, modifier, place of service, and claim-format requirements have been checked.
- The REMS and monitoring documentation is complete before the claim is released.
When Specialized Spravato Billing Support Makes Sense
Spravato billing becomes difficult to manage through occasional manual checks as treatment volume grows. One staff member may be tracking authorizations, another may coordinate specialty-pharmacy shipments, and a third may enter charges without seeing the acquisition record. Those handoffs are where duplicate billing, missed renewals, and unit errors begin.
Specialized support can centralize payer rules, authorization balances, inventory and acquisition indicators, claim review, denial trends, and appeals. This is particularly useful for practices expanding their mental health billing operations beyond routine E/M and psychotherapy claims.
Frequently Asked Questions
What is the 2026 HCPCS code for Spravato?
J0013 is the permanent HCPCS drug code for esketamine nasal spray, 1 mg, used in many non-Medicare drug billing scenarios. Medicare buy-and-bill claims may instead use G2082 or G2083. Always confirm the patient’s payer policy.
Is S0013 still valid for Spravato?
S0013 was replaced by J0013 for applicable 2026 dates of service. A payer may also require an existing authorization to be updated before it will accept J0013. Do not rely on a 2025 claim template for a 2026 service.
What are G2082 and G2083?
They are Medicare combination codes that include the medication, an established outpatient E/M service, supervision of Spravato self-administration, and two hours of observation. G2082 covers up to 56 mg, while G2083 covers more than 56 mg.
Can J0013 be billed with G2082 or G2083?
Generally, the drug should not be billed separately when the applicable G code already includes it. Adding J0013 may create duplicate billing. Follow the specific payer’s written guidance for the claim.
How many J0013 units are billed for 56 mg and 84 mg?
Because J0013 represents 1 mg, 56 mg generally equals 56 units and 84 mg generally equals 84 units when the payer accepts that code and unit methodology. Verify the payer’s instructions and reconcile the units with the administration record.
How is the two-hour Spravato observation period billed?
G2082 and G2083 include the observation period. In other payer scenarios, an E/M or prolonged-service pathway may be allowed when all code, time, supervision, and documentation requirements are met. The REMS monitoring requirement alone does not guarantee separate reimbursement.
Build the Claim Around the Actual Treatment Workflow
The most reliable Spravato claim begins before the patient arrives. Verify the benefit channel, authorization, acquisition method, current code, units, site of care, and documentation expectations. After treatment, reconcile the dose and services against the claim rather than relying on a standard charge ticket.
A payer-specific process is more work than one universal template, but it prevents costly contradictions between the authorization, medication source, clinical note, and submitted codes. Swift Medical Billing helps practices turn the Spravato billing and coding guide into a repeatable workflow for clean claims, denial follow-up, and compliant reimbursement.
